Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Foster City, CA, US. The stock last traded at $99.70, up 1.50% on the session, giving a market capitalisation of $6.08B. On trailing twelve-month figures it carries a trailing P/E of -6.85, a net margin of -139.2%. Its beta of 0.51 implies it has historically moved less than the broad market.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Mirum Pharmaceuticals, Inc. is most often compared with the following Healthcare names: